Skip to main content
Premium Trial:

Request an Annual Quote

Biothreat Detection Technology Developer BioFlyte Raises $1.25M in Seed Funding

NEW YORK — BioFlyte said on Tuesday that it has raised $1.25 million in seed funding, which the company said it will use to accelerate the development of its mass spectrometry-based biothreat detection device.

The round was led by venture capital firm Anzu Partners. In conjunction with the financing, Anzu Managing Partner David Seldin and Wayne Bryden, CEO of biodefense firm Zeteo Tech, have joined BioFlyte's board of directors.

BioFlyte's first product, the z750, is a handheld air sampler that is compatible with PCR, immunoassays, and fieldable mass spec instruments. The Albuquerque, New Mexico-based company is also developing an instrument, called z200, for the detection and identification of airborne opioids, microbes, and toxins in real-time.

The z200 is based on matrix-assisted laser desorption and ionization mass spectrometry technology licensed from Zeteo Tech.

"BioFlyte is commercializing some much-needed breakthrough technology for the biodefense community," Bryden said in a statement. "The z200 provides a presumptive identification in five minutes and can be quickly and inexpensively upgraded to detect new or emerging threats."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.